膀胱尿路上皮癌术后吉西他滨联合顺铂辅助化疗的疗效分析

目的:观察吉西他滨联合顺铂用于膀胱尿路上皮癌术后辅助化疗的安全性及疗效。方法:回顾分析复旦大学附属中山医院2012年2月—2013年1月30例TNM分期为T2-3N0-2M0的膀胱尿路上皮癌术后化疗患者的临床资料,包括给药方法、肿瘤复发率及药物相关不良反应情况。结果:30例患者化疗第1、8天给予吉西他滨1.0g/m2静脉滴注;化疗第2天起给予顺铂70 mg/m2,分2 d连续静脉滴注;每21 d重复,平均4个疗程。随访12个月,仅1例复发,复发率为3.33%;有4例出现2级白细胞下降不良反应,4例出现2级恶心不良反应,无患者出现3级以上不良反应。结论:吉西他滨联合顺铂用于膀胱尿路上皮癌术后辅助化疗安全性良好,对于预防术后肿瘤复发可能有一定作用,可以考虑用于术后患者的辅助化疗。

Efficacy of Gemcitabine plus Cisplatin Chemotherapy in Postoperative Patients with Urothelial Cell Carcinoma of the Bladder

Objective： To observe the safety and efficacy of adjuvant chemotherapy with gemcitabine plus cisplatin（GC） in post- operative patients with urothelial cell carcinoma of the bladder. Methods： The clinical datum of 30 postoperative patients with urothelial cell carcinoma of the bladder staged T2-3N0 2M0 who received adjuvant chemotherapy from Feb 2012 to Jan 2013 were retrospectively analyzed. The datum of dosage and administration,recurrence rate and side effects were included. Results： The 30 patients were treated with intravenous gemcitabine 1.0 g/m2 on day 1 and day 8 and cisplatin 70 mg/m2 on day 2 for 2 days. GC chemotherapy was repeated every 21 days. The patients received 4 cycles of chemotherapy in average and were fol- lowed up for I2 months. Tumor recurrence was found in only one patient and the recurrence rate was 3.33%. Four patients suffered from side effect of leucopenia in grade 2; four patients suffered from side effect of nausea in grade 2; and no grade 3 or severer side effect was observed. Conclusions： GC chemotherapy for the postoperative patients with urothelial cell carcinoma of the bladder is safe, and may reduce the recurrence rate, which makes it a good adjuvant chemotherapy for the postoperative patients with urothelial cell carcinoma of the bladder.